Virtual Library

Start Your Search

Yunha Nam



Author of

  • +

    P37 - Pathology - Biomarker Testing (ID 107)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P37.13 - Diagnostic Performance of Aptamer-Based Multiplex PCR Compared to Luminex Assay for Detection of Non-Small Cell Lung Cancer (ID 2904)

      00:00 - 00:00  |  Presenting Author(s): Yunha Nam

      • Abstract
      • Slides

      Introduction

      Although lung cancer screening using low-dose computed tomography reduces lung cancer mortality, the high false-positive rate, cost, and potential harms of diagnostic testing highlight the need for complementary diagnostic tools. We aimed to investigate the diagnostic performance of a protein signature classifier based on aptamer technology and multiplex real-time PCR in diagnosis of non-small cell lung cancer (NSCLC).

      Methods

      The participants included 48 patients diagnosed with NSCLC and 51 control subjects from Asan Medical Center, Seoul, South Korea. We investigated candidate biomarkers with a novel modified aptamer-based proteomic technology using multiplex real-time PCR and a 5-protein panel developed to discriminate lung cancer patients from controls. A naïve Bayesian classifier was trained using sera from 33 lung cancer patients and 35 controls. An independent set of 15 cases and 16 controls was used to verify performance of this classifier.

      Results

      We derived a 7-marker and 5-marker classifier using the Luminex assay and multiplex real-time PCR, respectively. The 5-protein panel assay was comprised of epidermal growth factor receptor 1, matrix metalloproteinase 7, KIT, and complement component 9. The 5-marker classifier resulted in 66.7% sensitivity with 92.2% specificity for whole stage, and 44.4% sensitivity with 92.2% specificity for stage I and II disease.

      Conclusion

      We have developed a 5-protein biomarker panel using multiplex real-time PCR to accurately identify NSCLC. The panel displayed similar diagnostic performance compared to a 7-protein biomarker-based Luminex assay. The high specificity in patients with NSCLC might help differentiate non-malignant pulmonary nodules in low-dose chest computed tomography screening.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.